165 related articles for article (PubMed ID: 6940687)
1. Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy.
Harris AL; Grahame-Smith DG; Potter CG; Bunch C
Clin Sci (Lond); 1981 Feb; 60(2):191-8. PubMed ID: 6940687
[TBL] [Abstract][Full Text] [Related]
2. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
Harris AL
Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
[No Abstract] [Full Text] [Related]
3. Cytosine arabinoside triphosphate production in human leukaemic myeloblasts: interactions with deoxycytidine.
Harris AL; Grahame-Smith DG
Cancer Chemother Pharmacol; 1981; 5(3):185-92. PubMed ID: 6945922
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of deamination of 14C-cytosine arabinoside (NSC-63878): a useful biologic assay for tetrahydrouridine (NSC-112907).
Furner RL; Mellett LB
Cancer Chemother Rep; 1975; 59(4):717-20. PubMed ID: 809135
[TBL] [Abstract][Full Text] [Related]
5. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
Heinemann V; Jehn U
Leukemia; 1990 Nov; 4(11):790-6. PubMed ID: 2232893
[No Abstract] [Full Text] [Related]
6. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
8. The relationship of cytosine arabinoside phosphorylation to inhibition of DNA synthesis in human leukaemic myeloblasts [proceedings].
Harris AL
Br J Clin Pharmacol; 1979 Apr; 7(4):424P-425P. PubMed ID: 286603
[No Abstract] [Full Text] [Related]
9. Effect of cytosine arabinoside on nuclear labelling of leukaemic myeloblasts with tritiated thymidine triphosphate.
Waetzin GL
Leuk Res; 1979; 3(1):7-13. PubMed ID: 294488
[No Abstract] [Full Text] [Related]
10. Assessment of drug sensitivity of human leukaemic myeloblasts. II. The toxic effects of cytosine arabinoside on 125IUdR-labelled human leukaemic myeloblasts in mice.
Sonis ST; Falcão R; MacLennan IC
Br J Cancer; 1977 Sep; 36(3):307-12. PubMed ID: 270373
[TBL] [Abstract][Full Text] [Related]
11. The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia.
Smyth JF; Robins AB; Leese CL
Eur J Cancer (1965); 1976 Jul; 12(7):567-73. PubMed ID: 1066282
[No Abstract] [Full Text] [Related]
12. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
[TBL] [Abstract][Full Text] [Related]
13. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.
Harris AL; Grahame-Smith DG
Cancer Chemother Pharmacol; 1982; 9(1):30-5. PubMed ID: 6958391
[TBL] [Abstract][Full Text] [Related]
14. Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.
Wermeling JR; Pruemer JM; Hassan FM; Warner A; Pesce AJ
Clin Chem; 1989 Jun; 35(6):1011-5. PubMed ID: 2731341
[TBL] [Abstract][Full Text] [Related]
15. Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
Coleman CN; Johns DG; Chabner BA
Ann N Y Acad Sci; 1975 Aug; 255():247-51. PubMed ID: 171992
[No Abstract] [Full Text] [Related]
16. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
Preisler HD; Rustum YM; Azarnia N; Priore R
Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
[TBL] [Abstract][Full Text] [Related]
17. Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.
Epstein J; Preisler H
Eur J Cancer (1965); 1981 Jun; 17(6):623-8. PubMed ID: 6946929
[No Abstract] [Full Text] [Related]
18. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Karp JE; Donehower RC; Dole GB; Burke PJ
Blood; 1987 Apr; 69(4):1134-40. PubMed ID: 3470054
[TBL] [Abstract][Full Text] [Related]
19. Multiple determinants of antimetabolite action in humans.
Rustum YM
Bull Cancer; 1979; 66(1):93-6. PubMed ID: 283838
[No Abstract] [Full Text] [Related]
20. Variation in sensitivity of DNA synthesis to ara-C in acute myeloid leukaemia.
Harris AL; Grahame-Smith DG
Br J Haematol; 1980 Jul; 45(3):371-9. PubMed ID: 6932952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
